MedPath

ETOPOPHOS

These highlights do not include all the information needed to use ETOPOPHOS safely and effectively. See full prescribing information for ETOPOPHOS. ETOPOPHOS(etoposide phosphate) for injection, for intravenous useInitial U.S. Approval: 1983

Approved
Approval ID

7499fc35-fae8-44ad-bbab-9a1a589bf3ee

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 13, 2023

Manufacturers
FDA

H2-Pharma, LLC

DUNS: 028473634

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

etoposide phosphate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code61269-410
Application NumberNDA020457
Product Classification
M
Marketing Category
C73594
G
Generic Name
etoposide phosphate
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateDecember 16, 2019
FDA Product Classification

INGREDIENTS (3)

SODIUM CITRATE, UNSPECIFIED FORMInactive
Quantity: 32.7 mg in 1 1
Code: 1Q73Q2JULR
Classification: IACT
DEXTRAN 40Inactive
Quantity: 300 mg in 1 1
Code: K3R6ZDH4DU
Classification: IACT
etoposide phosphateActive
Quantity: 100 mg in 1 1
Code: 528XYJ8L1N
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ETOPOPHOS - FDA Drug Approval Details